MedAxiom Announces Industry Partnership with Genetesis, Inc.

Genetesis, Inc. is transforming patient care from invasive, stress-induced, lengthy procedures, to non-invasive, at rest, rapid testing.

Partner News | Published: Wednesday, February 5, 2020


MedAxiom, the nation’s leading cardiovascular healthcare membership organization and performance community, is excited to announce its industry partnership with Genetesis, Inc., a medical technology company with a vision to improve patients’ cardiovascular health, outcomes, and quality of life. 

“Genetesis is striving to improve efficiency in ruling out and detecting heart disease through magnetocardiography (MCG), an imaging modality that measures magnetic fields produced by the natural electrical activity of the heart. Genetesis’s CardioFlux has overcome adoption challenges and expenses by eliminating the need for magnetically shielded rooms and liquid helium cooling.” said Joe Sasson Ph.D., EVP of MedAxiom Ventures. “We are excited to welcome them as a MedAxiom Industry Partner and bring awareness and understanding of their opportunities to our membership community.”

Genetesis is dedicated to providing biomagnetic imaging solutions to improve hospital efficiency and throughput by serving as a rapid rule-out tool for chest pain triage in the emergency department. Their cloud-based imaging software integrates with both clinical and administrative systems to accept scan orders from physicians and deliver results directly into each hospital's workflow.

"While previous studies of magnetocardiography have yielded promise in the detection of coronary artery disease, this is the first time a scalable iteration of this technology has been made available to emergency medicine in their difficult task of diagnosing ACS." Dr. Alisa Niksch, Genetesis Chief Medical Officer, states. "This data has given Genetesis the momentum to expand research into other populations at risk for ischemic heart disease."

Genetesis’s non-invasive biomagnetic tool, CardioFlux Magnetocardiograph™ (MCG) is FDA Cleared and records the magnetic fields that are naturally generated by the electrical activity of the heart, from a 90 second scan. This advanced imaging device is comprised of a magnetic shield and an array of 36 sensors used to isolate and measure the heart's magnetic field.

CardioFlux has the potential to substantially reduce cost and wait times while improving patient experience and outcomes.

MedAxiom members will have an opportunity to learn more about Genetesis at the CV Transforum Spring’20 conference, April 23-25, in Ponte Vedra Beach, FL.

Learn more about Genetesis at https://genetesis.com.

About MedAxiom

MedAxiom, an American College of Cardiology Company, is the cardiovascular community’s largest membership and resources network and the leading cardiovascular-specific consulting team in the U.S. MedAxiom is transforming cardiovascular care by combining the knowledge and power of more than 400 cardiovascular organization members and thousands of providers, administrators and clinicians. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience.

For additional information, visit www.MedAxiom.com.

About Genetesis, Inc.

Genetesis, Inc. is a medical technology company focused on redefining the way myocardial ischemia and coronary artery disease are detected. By combining CardioFlux, our noninvasive biomagnetic imaging technology, with proprietary cloudbased web services and machine-learning capabilities, they seek to become the standard of care for diagnosis of clinically significant myocardial ischemia in the acute care setting. Genetesis was founded in 2013 and is based in Mason, Ohio.

For additional information, visit: https://genetesis.com.